These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
628 related articles for article (PubMed ID: 18823036)
1. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Dash A; Pettus JA; Herr HW; Bochner BH; Dalbagni G; Donat SM; Russo P; Boyle MG; Milowsky MI; Bajorin DF Cancer; 2008 Nov; 113(9):2471-7. PubMed ID: 18823036 [TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE; Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978 [TBL] [Abstract][Full Text] [Related]
3. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. Weight CJ; Garcia JA; Hansel DE; Fergany AF; Campbell SC; Gong MC; Jones JS; Klein EA; Dreicer R; Stephenson AJ Cancer; 2009 Feb; 115(4):792-9. PubMed ID: 19127557 [TBL] [Abstract][Full Text] [Related]
4. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S; Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy. Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W; J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894 [TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer. Meleis L; Moore R; Inman BA; Harrison MR J Oncol Pharm Pract; 2020 Mar; 26(2):330-337. PubMed ID: 31081469 [TBL] [Abstract][Full Text] [Related]
11. Downstaging of Muscle-Invasive Bladder Cancer Using Neoadjuvant Gemcitabine and Cisplatin or Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Single Regimens or as Switch Therapy Modalities. Ruplin AT; Spengler AMZ; Montgomery RB; Wright JL Clin Genitourin Cancer; 2020 Oct; 18(5):e557-e562. PubMed ID: 32201105 [TBL] [Abstract][Full Text] [Related]
12. Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer. Matsubara N; Mukai H; Naito Y; Nezu M; Itoh K Asia Pac J Clin Oncol; 2013 Dec; 9(4):310-7. PubMed ID: 23127231 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer. Niedersüss-Beke D; Puntus T; Kunit T; Grünberger B; Lamche M; Loidl W; Böhm R; Kraischits N; Kudlacek S; Schramek P; Meran JG Oncology; 2017; 93(1):36-42. PubMed ID: 28399521 [TBL] [Abstract][Full Text] [Related]
14. Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy. North S; El-Gehani F; Santos C; Ghosh S; Lai R; Cass CE; Mackey JR J Urol; 2014 Jan; 191(1):35-9. PubMed ID: 23851183 [TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California. Fairey AS; Daneshmand S; Quinn D; Dorff T; Dorin R; Lieskovsky G; Schuckman A; Cai J; Miranda G; Skinner EC Urol Oncol; 2013 Nov; 31(8):1737-43. PubMed ID: 23141776 [TBL] [Abstract][Full Text] [Related]
16. [Relative efficacy of neoadjuvant gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management for muscle-invasive bladder cancer]. Kawamura N; Matsushita M; Okada T; Ujike T; Nin M; Tsujihata M Hinyokika Kiyo; 2013 May; 59(5):277-81. PubMed ID: 23719134 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin. van de Putte EE; Mertens LS; Meijer RP; van der Heijden MS; Bex A; van der Poel HG; Kerst JM; Bergman AM; Horenblas S; van Rhijn BW World J Urol; 2016 Feb; 34(2):157-62. PubMed ID: 26184106 [TBL] [Abstract][Full Text] [Related]
18. Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC. Lee Y; Kim YS; Hong B; Cho YM; Lee JL J Cancer Res Clin Oncol; 2021 Nov; 147(11):3421-3429. PubMed ID: 33715088 [TBL] [Abstract][Full Text] [Related]
19. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Siefker-Radtke AO; Dinney CP; Shen Y; Williams DL; Kamat AM; Grossman HB; Millikan RE Cancer; 2013 Feb; 119(3):540-7. PubMed ID: 22914978 [TBL] [Abstract][Full Text] [Related]